Sotyktu becomes the first approved TYK2 inhibitor (2022)
The U.S. Food and Drug Administration approved Bristol Myers Squibb's deucravacitinib, sold as Sotyktu, for moderate-to-severe plaque psoriasis. It was the first drug to block TYK2, a specific immune-signaling enzyme, rather than the broader JAK family.
Sotyktu gave dermatologists a once-daily pill for psoriasis with a cleaner safety label than older JAK drugs.
It proved the TYK2 target could reach the market and spurred rivals to test the mechanism in other skin diseases.
Soficitinib works on the same target. Sotyktu shows the class can win approval, but it is not cleared for eczema, the gap InnoCare is chasing.
